Gastrointestinal Cancer
Disease Group
Gastrointestinal Cancer
Disease Group Profile
The GI Oncology Disease Group has a highly collaborative team of investigators who are committed to developing innovative therapeutic strategies for patients with significant, unmet need. We have launched disease-specific umbrella trials to identify patients with actionable molecular targets and treat those patients with best-in-class therapies. Moving forward, the GI team hopes to leverage its strengths to expand its portfolio of targets and therapies.
Disease Group Leaders
Tanios Bekaii-Saab, M.D.
ACCRU Chair, Board of Directors ChairMayo Clinic Arizona
Tanios Bekaii-Saab, M.D. is a medical oncologist focusing on the treatment of gastrointestinal malignancies. He is the leader of the gastrointestinal cancer program for the Mayo Clinic Enterprise Cancer Center. Dr. Bekaii-Saab has served on various committees for ACCRU since 2012. He currently serves as the Consortium and Board of Director Chair for ACCRU.
John Strickler, M.D.
Duke University Medical Center
John Strickler, M.D. is an Associate Professor at Duke University, where he is the Associate Director of Clinical Research – GI Oncology and Co-Leader of the Molecular Tumor Board. Dr. Strickler’s clinic specializes on the treatment of gastrointestinal malignancies, with a particular emphasis on colorectal cancer.
Disease Group Clinical Trials
2018-07
Blood and Stool Sample Collection in Subjects with a Diagnosis of Colorectal Cancer or Colorectal Lesion
ACCRU-GI-1809
A Randomized Phase II Study of Regorafenib Followed by Anti-EGFR monoclonal antibody therapy Versus the Reverse Sequencing for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin and irinotecan (REVERCE II)
ACCRU-GI-1810
Ramucirumab Plus trifluridine/tipiracil (TAS-102) for Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: An Investigator-Initiated, Randomized Non-inferiority Phase 2 Study
ACCRU-GI-1907
BrafPanc: A Phase II Trial of Binimetinib in combination with Encorafenib in patients with Pancreatic Malignancies and a somatic BRAFV600E mutation
ACCRU-GI-1920
Neoadjuvant Regorafenib Plus Durvalumab (MEDI4736) in Patients with High-risk Hepatocellular Carcinoma
ACCRU-GI-2008
A Phase II Randomized Study of Atezolizumab plus Multi-Kinase Inhibitor Versus Multi-Kinase Inhibitor Alone in Subjects with Unresectable, Advanced Hepatocellular Carcinoma Who Previously Received Atezolizumab and Bevacizumab
ACCRU-GI-2017
A Phase II Study of Nivolumab plus Ipilimumab in advanced HCC patients who have progressed on first-line Atezolizumab + Bevacizumab
ACCRU-ICRN-1701
A Phase I, Single center, Open label, Dose De-escalation and Expansion Study of gemcitabine and cisplatin with AG120 or INCB054828 for advanced cholangiocarcinoma
ACCRU-ICRN-1702
A Phase II study of Olaparib in patients with advanced biliary tract cancer expressing aberrant DNA repair
AG0315OG/CTC0140
INTEGRATE IIb: A Randomised Phase III Open Label Study of regorafenib + nivolumab vs standard chemotherapy in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)
RegoNivo vs Standard of Care Chemotherapy in AGOC (INTEGRATEIIb) »
ACCRU-GI-2003
3T: A Phase II, Open Label Study of Tucatinib Combined with Trastuzumab and TAS-102 in Molecularly Selected Patients with HER2+ Metastatic Colorectal Cancer
2018-01
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Stool Collection Sub-Study of Exact Sciences Protocol 2018-01 »
ACCRU-GI-1603
Phase I Study of Irinotecan Liposome (nal-IRI), Fluorouracil and Rucaparib in the Treatment of Select Gastrointestinal Metastatic Malignancies Followed by a Phase Ib of First and Second Line Treatment of both Unselected and Selected ( for BRCA 1/2 and PALB2 Mutations) Patients with Metastatic Adenocarcinoma of the Pancreas then Followed by a Phase II Study of First Line Treatment of Selected Patients with Metastatic Adenocarcinoma of the Pancreas with Genomic Markers (Signature) of Homologous Recombination Deficiency (HRD)
ACCRU-GI-1611
COLOMATE: Colorectal Cancer Liquid Biopsy Screening Protocol for Molecularly Assigned ThErapy
ACCRU-GI-1618
Combination of MEK Inhibitor Binimetinib and CDK4/6
Inhibitor Palbociclib in KRAS and NRAS Mutant Metastatic Colorectal Cancers
ACCRU-GI-1623
PULSE: A Randomized, Phase II Open Label Study of Panitumumab Rechallenge Versus Standard Therapy after Progression on Anti-EGFR Therapy in Patients with Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
ACCRU-GI-1701
A Phase II, Multicenter, Single-Arm Study of Pemigatinib in Patients with Metastatic Colorectal Cancer Harboring FGFR Alterations
ARRAY-818-302
A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetu ximab or Infusional 5-Fluorouracil (5- FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetu ximab With a Safety Lead-in of Encorafenib Binimetinib Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
BBI608-336
A Phase III Clinical Trial of BBI608 Plus Weekly Paclitaxel vs. Placebo Plus Weekly Paclitaxel in Adult Patients With Advanced, Previously Treated
CanStem111P
A Phase III Study of BBI- 608 Plus Nab- Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinom a
CanStem303C
A Phase III Study of BBI- 608 in Combination With 5- Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CRC)
D-US-60010-001
An open-label, randomised, multicentre, phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracil/leucovorin versus nab-paclitaxel plus gemcitabine in subjects who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas
M14-064
Phase 2 Study Comparing Efficacy and Safety of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Metastatic Colorectal Cancer Previously Treated with Fluoropyrimidine/Oxaliplatin-Based Regimen and Bevacizumab
MC0248
A Phase I Dose-Finding Study and a Randomized Phase II Study of ALIMTA Plus Oxaliplatin Versus Oxaliplatin Plus 5-Fluorouracil and Leucovorin (FOLFOX 4 Regimen) in the First-Line Treatment of Patients With Locally Advanced Unresectable or Stage IV Colorectal Cancer
MM-111-13-02-04
Randomized, Open Label, Phase 2 Study of MM-111 and Paclitaxel With Trastuzumab in Patients With HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Who Have Failed Front Line Metastatic or Locally Advanced Therapy
MORAb-004-202-CRC
A Randomized, Double-Blind, Placebo-controlled Study of the Efficacy & Safety of Monotherapy MORAb-004 Plus Best Supportive Care in Subjects With Chemorefractory Metastatic Colorectal Cancer
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO) »
MS202202-0002
A Phase II Single-Arm Study to Investigate Tepotinib Combined with Cetuximab in RAS/BRAF Wild-Type Left- Sided Metastatic Colorectal Cancer (mCRC) Patients Having Acquired Resistance to Anti-EGFR Antibody Targeting Therapy Due to MET Amplification
RU021205I
Randomized Phase II Study of Adjuvant Regorafenib
Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors »
RU021212I
Randomized Phase II Study of Adjuvant Regorafenib vs Placebo in Patients with Node Positive Esophageal Cancer that Completed Pre-operative Therapy
RU021302I
BOND-3:A Randomized, Double-blind, Placebo-controlled Phase II Trial of Irinotecan, Cetuximab, and Bevacizumab Compared with Irinotecan, Cetuximab, and Placebo in RAS-Wildtype, Irinotecan-refractory Metastatic Colorectal
RU021407I
Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients with Refractory Metastatic Colorectal Cancer (mCRC)
RU021416I
BACCI: A Phase II Randomized, Double-Blind, Placebo- Controlled Study of Capecitabine Bevacizumab plus Atezolizumab versus Capecitabine Bevacizumab plus Placebo in Patients with Refractory Metastatic Colorectal Cancer
RU021502I
A Multicenter Phase II Study of Pembrolizumab (MK-3475) in Patients with Advanced Small Bowel Adenocarcinoma S